Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing
Authors:
- Diana F. ClarkeDCDiana F. Clarke
- Edward P. AcostaEAEdward P. Acosta
- Matthew L. RizkMRMatthew L. Rizk
- Yvonne J. BrysonYBYvonne J. Bryson
- Stephen A. SpectorSSStephen A. Spector
- Lynne M. MofensonLMLynne M. Mofenson
- Edward HandelsmanEHEdward Handelsman
- Hedy TepplerHTHedy Teppler
- Carolee WelebobCWCarolee Welebob
- Deborah PersaudDPDeborah Persaud
- Mae P. CababasayMCMae P. Cababasay
- JiaJia WangJWJiaJia Wang
- 1 November 2014
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 67 (3) , 310-315
Abstract
International Maternal Pediatric Adolescent AIDS Clinical Trials P1097 was a multicenter trial to determine washout pharmacokinetics and safety of in utero/intrapartum exposure to raltegravir in infants born to HIV-infected pregnant women receiving raltegravir-based antiretroviral therapy. Twenty-two mother–infant pairs were enrolled; evaluable pharmacokinetic data were available from 19 mother–infant pairs. Raltegravir readily crossed the placenta, with a median cord blood/maternal delivery plasma raltegravir concentration ratio of 1.48 (range, 0.32–4.33). Raltegravir elimination was highly variable and extremely prolonged in some infants; [median t1/2 26.6 (range, 9.3–184) hours]. Prolonged raltegravir elimination likely reflects low neonatal UGT1A1 enzyme activity and enterohepatic recirculation. Excessive raltegravir concentrations must be avoided in the neonate because raltegravir at high plasma concentrations may increase the risk of bilirubin neurotoxicity. Subtherapeutic concentrations, which could lead to inadequate viral suppression and development of raltegravir resistance, must also be avoided. Two ongoing International Maternal Pediatric Adolescent AIDS Clinical Trials studies are further investigating the pharmacology of raltegravir in neonates.Keywords
This publication has 14 references indexed in Scilit:
- One-Month Transplacental Pharmacokinetics of Raltegravir in a Premature Newborn after Short-Course Treatment of the HIV-1-Infected MotherAntimicrobial Agents and Chemotherapy, 2013
- Absence of Detectable HIV-1 Viremia after Treatment Cessation in an InfantNew England Journal of Medicine, 2013
- Raltegravir In Vitro Effect on Bilirubin BindingThe Pediatric Infectious Disease Journal, 2013
- Raltegravir in the prevention of mother-to-child transmission of HIV-1AIDS, 2012
- Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV InfectionNew England Journal of Medicine, 2012
- High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant womenAIDS, 2010
- Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studiesExpert Opinion on Drug Metabolism & Toxicology, 2010
- A sensitive HPLC–MS–MS method for the determination of raltegravir in human plasmaJournal of Chromatography B, 2008
- Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of GestationPediatrics, 2004
- Bilirubin–Albumin Binding and Free BilirubinJournal of Perinatology, 2001